Science Advisory Committee on Health Products Containing Cannabis (SAC-HPCC): Agenda for November 5, 2021 web conference

This web conference will focus on a review and refinement of the points of consensus reached by members during their summer and fall meetings related to the safety, efficacy and quality of cannabidiol (CBD) when used for therapeutic purposes. Discussions will touch on considerations related to evidence requirements and suitability for use without practitioner oversight, as well as priorities of the research and medical community. Members will also review input received from key external experts on the safety and efficacy of CBD.

Time
Eastern Time (ET)
Agenda – November 5, 2021
2:00 pm to 5:00 pm ET

1

2:00 – 2:05 pm

Welcome and introductory remarks
Presenters: Committee Co-Chairs

  1. Tech verification
  2. Meeting recording

2

2:05 – 2:15 pm

Administrative items
Presenters: Committee Co-Chairs

  1. Updates to declarations of affiliations and interests
  2. Approval of agenda and October 4, 2021 record of proceedings
  3. Update on the writing of the Committee’s report

3

2:15 – 2:45 pm

Review of input received from external experts
Facilitators: Committee Co-Chairs

  1. Review of responses provided from external experts on CBD safety and efficacy questions
  2. Committee discussion on input received

4

2:45 – 3:15 pm

Committee review and discussion on points of consensus related to CBD safety
Facilitators: Committee Co-Chairs

  1. Review of points of consensus reached previously on CBD safety
  2. Continued discussion and elaboration of related advice

5

3:15 – 3:25 pm

Break

6

3:25 – 4:20 pm

Committee review and discussion on points of consensus related to CBD efficacy, as well as related evidence requirements and suitability for use without practitioner oversight
Facilitators: Committee Co-Chairs

  1. Review of points of consensus reached previously on CBD efficacy
  2. Continued discussion and elaboration of related advice, including appropriate evidence standards
  3. Discussion of evidence requirement considerations and suitability for use without practitioner oversight

7

4:20 – 4:35 pm

Committee review and discussion on points of consensus related to CBD quality
Facilitators: Committee Co-Chairs

  1. Review of points of consensus reached previously on CBD quality
  2. Continued discussion and elaboration of related advice

8

4:35 – 4:50 pm

Committee discussion on evidence gaps and priorities of the research and medical community
Facilitators: Committee Co-Chairs

  1. Review of evidence gaps and priority areas previously discussed
  2. Continued discussion and elaboration of related advice

9

4:50 – 5:00 pm

Wrap up and next steps

Presenters: Committee Co-Chairs

Page details

Date modified: